ReviewCurrent atherosclerosis reports2025
Self-DNA by Activating the CGAS-STING1 Pathway Contributes to the Pathogenesis of Atherosclerosis.
Review in Current atherosclerosis reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
purpose of reviewTo discuss the role of self-DNA in activating the cytosolic DNA-sensing proteins (CDSPs) and inducing low-grade inflammation in the vessel wall in coronary atherosclerosis. RECENT
findingsThe cytosolic self-DNA, released from the nuclear or mitochondrial DNA in response to internal and external stressors, is sensed by the cytosolic CDSPs, which activate a cascade of molecular events that lead to the expression of interferon-stimulated genes and pro-inflammatory cytokines. The focus of this review is on the cGMP-cAMP synthase (CGAS) - stimulator of interferon response cGAMP interactor 1 (STING1) pathway. Activation of the CGAS-STING1 pathway has been documented in the coronary arteries in human patients with atherosclerosis. Likewise, experimental data implicate the activation of the CGAS-STING1 pathway in response to cytosolic self-DNA in the pathogenesis of atherosclerosis and cardiac remodeling, as well as clinical outcomes after myocardial infarction. Genetic and pharmacological inhibition of the CGAS-STING1 pathway, by and large, has shown salubrious effects in attenuating atherosclerosis and improving cardiac function and prolonging survival after myocardial infarction in experimental models. The data support the pathogenic role of the cytosolic self-DNA, released from the nuclear and/or mitochondrial genomes in response to the DNA-damaging agents, in inducing a low-grade inflammation in the vessel wall and contributing to the pathogenesis of coronary atherosclerosis and cardiac remodeling post-myocardial infarction. Whether the salubrious effects of targeting the CGAS-STING1 pathway, observed in the experimental models, would extend to human patients with coronary atherosclerosis or myocardial infarction is an open empirical question that awaits being tested after careful consideration of the potential fortuitous effects.
Indexed as
Identifiers
41037234What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.